
Johnson & Johnson company profile
$285.75+0.79%Close 13 Nov 2026 · Market value $684.4B
About Johnson & Johnson
Johnson & Johnson is a healthcare company that researches, develops, manufactures and sells a broad range of products through two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment offers prescription medicines across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism, distributed to retailers, wholesalers, distributors, hospitals and healthcare professionals. The MedTech segment develops and manufactures procedural products in cardiovascular, orthopaedics, surgery and vision, used by physicians, hospitals, eye care professionals and clinics. The Company operates through subsidiaries in virtually all countries of the world.
A summary of the business section of the company's latest annual report, filed 11 Feb 2026.
Company facts
| Ticker | JNJ · NYSE |
|---|
| Sector | Healthcare |
|---|
| Industry | Pharmaceuticals |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 28 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 200406 |
|---|
| Latest annual report | 10-K, filed 11 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| J. Duato | CEO and Chairman of the Board · Director | 1.4M | Open-market sale, 13 Aug 2026 |
|---|
| J. Taubert | EVP, WWC. Innovative Medicine | 748K | Open-market sale, 17 Aug 2026 |
|---|
| T. Schmid | EVP, WW Chair, MedTech | 161K | Open-market sale, 2 Sep 2026 |
|---|
| M. A. Weinberger | Director | 12.0K | Open-market purchase, 12 Dec 2024 |
|---|
| J. G. Morikis | Director | 1.8K | Open-market purchase, 26 Nov 2025 |
|---|
| Forminard Elizabeth | EVP, Chief Legal Officer | — | Open-market sale, 6 Aug 2026 |
|---|
| Broadhurst Vanessa | EVP, Global Corp Affairs | — | Option exercise, 20 Jul 2026 |
|---|
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | — | Open-market sale, 11 Jun 2026 |
|---|
| REED JOHN C | EVP, Innovative Medicine, R&D | — | Shares withheld for tax, 1 May 2026 |
|---|
| Decker Robert J | VP Corporate Controller | — | Open-market sale, 27 Feb 2026 |
|---|
| Swanson James D. | EVP, CIO | — | Open-market sale, 17 Feb 2026 |
|---|
| Wolk Joseph J | Exec VP, CFO | — | Option exercise, 17 Feb 2026 |
|---|
| Mulholland Kristen | EVP, Chief HR Officer | — | Option exercise, 15 Feb 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
JNJ in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.